Cytosorbents Corporation
CTSO
$0.79
$0.045.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.09% | 11.43% | 6.79% | 6.06% | -19.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.09% | 11.43% | 6.79% | 6.06% | -19.48% |
| Cost of Revenue | 24.44% | 36.21% | 9.85% | -17.17% | -55.44% |
| Gross Profit | 12.57% | 5.00% | 5.85% | 15.72% | 2.92% |
| SG&A Expenses | -4.33% | -7.14% | -9.53% | -6.97% | 5.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.41% | -10.58% | -17.28% | -20.49% | -17.68% |
| Operating Income | 38.23% | 36.07% | 42.78% | 46.15% | 15.27% |
| Income Before Tax | 38.28% | 55.96% | 37.15% | 24.40% | 16.28% |
| Income Tax Expenses | -157.07% | -107.79% | -107.79% | -107.79% | 25.53% |
| Earnings from Continuing Operations | 46.34% | 61.06% | 41.36% | 28.08% | 15.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.34% | 61.06% | 41.36% | 28.08% | 15.84% |
| EBIT | 38.23% | 36.07% | 42.78% | 46.15% | 15.27% |
| EBITDA | 40.76% | 38.22% | 45.08% | 48.70% | 17.07% |
| EPS Basic | 50.97% | 65.13% | 50.29% | 41.16% | 28.05% |
| Normalized Basic EPS | 44.27% | 60.38% | 46.55% | 38.05% | 25.40% |
| EPS Diluted | 50.79% | 64.98% | 50.14% | 41.03% | 27.88% |
| Normalized Diluted EPS | 43.76% | 60.01% | 46.55% | 38.05% | 25.40% |
| Average Basic Shares Outstanding | 14.81% | 16.45% | 18.39% | 22.00% | 19.38% |
| Average Diluted Shares Outstanding | 16.98% | 18.73% | 18.39% | 22.00% | 19.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |